Global Dialysis Market Report by Type, Product & Services, End User, Countries and Companies Analysis 2026-2034

Global Dialysis Market Size and Forecast

Global Dialysis Market is projected to grow from US$ 121.54 Billion in 2025 to US$ 178.92 Billion by 2034, expanding at a Compound Annual Growth Rate (CAGR) of 4.39% during 2026–2034. This growth is primarily driven by the rising global burden of chronic kidney disease (CKD), along with increasing incidences of diabetes and hypertension, which are major contributors to kidney failure. The growing need for renal replacement therapies, including hemodialysis and peritoneal dialysis, is further supporting market expansion. In addition, continuous advancements in dialysis technologies, equipment, and treatment systems are improving patient care and treatment efficiency.

What is Dialysis and Its Uses & Popularity Worldwide

Dialysis is a renal replacement therapy used to remove waste products, excess fluids, and electrolytes from the blood when the kidneys can no longer perform these functions adequately. The two principal forms are hemodialysis, in which blood is filtered through an external dialysis machine, and peritoneal dialysis, which uses the lining of the abdomen as a natural filtering membrane. Dialysis is primarily used to manage kidney failure and can be provided in hospitals, specialized dialysis centers, or increasingly through home-based treatment programs.

The global importance of dialysis is increasing as chronic kidney disease (CKD), diabetes, hypertension, and population ageing contribute to growing kidney failure burdens. WHO estimates that approximately 674 million people worldwide live with CKD, with most affected individuals residing in low- and middle-income countries. Dialysis remains an essential treatment where kidney transplantation is unavailable, unsuitable, or delayed. Its worldwide adoption is supported by expanding renal-care infrastructure, greater disease awareness, improved dialysis technologies, and efforts to increase equitable access to kidney replacement therapy.

Number of People with Diabetes Worldwide and by IDF Region (Age 20–79), 2024–2050

• Worldwide: The number of adults aged 20–79 living with diabetes is projected to increase from 588.7 million in 2024 to 852.5 million by 2050, representing a 45% increase.
• Africa (AFR): Diabetes prevalence is projected to rise from 24.6 million in 2024 to 59.5 million by 2050, the highest regional growth rate at 142%.
• Europe (EUR): The diabetic population is expected to increase from 65.6 million to 72.4 million, representing a 10% increase.
• Middle East & North Africa (MENA): The number of people with diabetes is forecast to grow from 84.7 million to 162.6 million, a 92% increase.
• North America & Caribbean (NAC): Diabetes cases are projected to rise from 56.2 million to 68.1 million, equivalent to a 21% increase.
• South & Central America (SACA): The diabetic population is expected to increase from 35.4 million to 51.5 million, representing a 45% increase.
• South-East Asia (SEA): Diabetes cases are forecast to grow from 106.9 million to 184.5 million, a substantial 73% increase.
• Western Pacific (WP): The region is projected to increase from 215.4 million people with diabetes in 2024 to 253.8 million by 2050, representing an 18% increase.

Source: International Diabetes Federation (IDF) Diabetes Atlas, 11th Edition, 2025.

Top 10 Countries with the Largest Aging Population Worldwide

• China: Approximately 193.8 million people aged 65 and above, representing the largest elderly population among the listed countries.
• India: Around 97.7 million people aged 65+, placing India second.
• United States: Approximately 57.1 million elderly people, making it the third-largest population aged 65+.
• Japan: Around 37.4 million people aged 65 and above.
• Russia: Approximately 22.8 million people aged 65+.
• Brazil: Around 21.3 million elderly people.
• Indonesia: Approximately 18.9 million people aged 65 and above.
• Germany: Around 18.8 million elderly people.
• France: Approximately 14.7 million people aged 65+.
• Italy: Around 14.2 million people aged 65 and above.

Source: World Population Review.

Growth Drivers of the Global Dialysis Market

Rising Global Burden of Chronic Kidney Disease

The increasing prevalence of chronic kidney disease is a major factor supporting demand for dialysis services and equipment worldwide. WHO estimates that approximately 674 million people have CKD globally, equivalent to around 9% of the world’s population, with the majority living in low- and middle-income countries. CKD can progress to kidney failure, the most severe stage of the disease, when dialysis or kidney transplantation may be required to sustain life. Diabetes and hypertension are particularly important contributors to the growing renal disease burden. WHO reports that kidney disease occurs in approximately 1 in 5 people with hypertension and 4 in 10 people with diabetes, highlighting the large population at risk of progressive kidney damage. Increasing life expectancy and population ageing are also expanding the number of individuals requiring long-term renal care. As more patients progress toward advanced kidney disease, demand is increasing for hemodialysis machines, dialyzers, dialysis solutions, vascular-access products, monitoring systems, and related consumables. This expanding patient pool provides a sustained foundation for global dialysis market growth.

Increasing Diabetes, Hypertension, and Ageing Population

The growing prevalence of metabolic and cardiovascular risk factors is increasing the need for kidney replacement therapies. Diabetes and hypertension are among the major conditions associated with CKD progression, while ageing populations face a higher risk of chronic diseases and declining kidney function. WHO identifies diabetes and hypertension as important drivers of the global kidney disease burden and emphasizes improved kidney-health management among people with these conditions. The increasing number of patients living with multiple chronic conditions is therefore expanding the population requiring regular renal monitoring and, in advanced cases, dialysis. Demand is particularly significant because dialysis is generally a continuing treatment for individuals who develop kidney failure and cannot immediately receive transplantation. Healthcare systems are consequently investing in dialysis centers, trained renal-care professionals, advanced treatment machines, and home dialysis programs. At the same time, greater awareness of CKD screening and early disease management is encouraging earlier identification of patients at risk of kidney failure. These demographic and epidemiological trends are expected to sustain demand for dialysis services and products across developed and emerging markets.

Technological Advancements and Expansion of Home Dialysis

Technological innovation is creating new opportunities for the dialysis market by improving treatment efficiency, monitoring, portability, and patient convenience. Manufacturers are developing increasingly sophisticated dialysis machines, automated peritoneal dialysis systems, digital monitoring platforms, and connected technologies that can support treatment outside conventional dialysis centers. Home-based dialysis is particularly important because it can provide greater flexibility for suitable patients while reducing the need for frequent visits to centralized facilities. Technological improvements are also supporting more precise fluid management, treatment monitoring, safety features, and remote clinical oversight. These developments are relevant to the large global population affected by CKD, particularly because WHO identifies inequitable access to kidney replacement therapies as a major worldwide challenge. Digital healthcare infrastructure can also enable healthcare professionals to monitor treatment data and identify potential complications more efficiently. As healthcare providers seek cost-effective and patient-centered renal-care models, investments in portable, automated, connected, and home-use dialysis technologies are expected to contribute to market expansion while improving access to treatment in geographically dispersed populations.

Challenges of the Global Dialysis Market

High Treatment Costs and Unequal Access to Dialysis

High treatment costs and unequal availability of renal replacement therapy remain major challenges for the global dialysis market. Dialysis requires specialized machines, dialyzers, fluids, vascular-access equipment, trained healthcare professionals, electricity, water-treatment systems, and regular clinical monitoring. These requirements can create substantial financial and infrastructure burdens, particularly in low- and middle-income countries. WHO has highlighted significant global inequities in access to kidney care and reports that many developing countries provide limited coverage for kidney replacement therapies, including dialysis and transplantation. In some settings, patients must pay substantial costs out of pocket, increasing the risk of catastrophic healthcare expenditure. The concentration of dialysis infrastructure in urban and higher-income areas can also leave rural and underserved populations with limited access to treatment. Consequently, the number of people who need dialysis does not necessarily translate directly into treatment demand because affordability and availability can restrict utilization. Expanding insurance coverage, public healthcare investment, decentralized dialysis centers, and lower-cost technologies remains important for addressing this challenge.

Shortage of Skilled Professionals and Infrastructure Requirements

Dialysis delivery depends on specialized infrastructure and trained healthcare personnel, creating operational challenges for healthcare systems with limited resources. Dialysis centers require reliable electricity and water supplies, specialized equipment, infection-control systems, appropriate facilities, and qualified nephrologists, nurses, technicians, and other healthcare workers. These requirements can make it difficult to expand dialysis services rapidly in rural and resource-constrained regions. WHO notes that inequitable access to healthcare workers and kidney replacement therapies contributes to preventable deaths among people with kidney disease. The challenge becomes more significant as the global CKD population grows and demand for kidney replacement therapy increases. In addition, dialysis is generally a recurring treatment, meaning healthcare systems must maintain equipment, consumables, staffing, and clinical support over extended periods rather than providing a one-time intervention. Developing countries may therefore face difficulties maintaining consistent treatment capacity even when dialysis equipment becomes available. Investments in workforce training, water and power infrastructure, decentralized care, home dialysis, and digital monitoring can help address these limitations.

Dialysis Treatment Launches Worldwide

1. Fresenius Medical Care 5008X CAREsystem – United States, 2025
   Fresenius Medical Care began introducing the 5008X CAREsystem for high-volume hemodiafiltration (HVHDF) in selected U.S. clinics in 2025. The system combines convection and diffusion and was designed to expand access to HVHDF, a dialysis therapy already used extensively in Europe and other regions. A broader U.S. commercial launch is planned for 2026.
2. NxStage Versi HD with GuideMe Software – United States, 2024
   Fresenius Medical Care launched the NxStage Versi HD with GuideMe Software, a home hemodialysis system designed to simplify treatment and improve the learning experience for patients and caregivers. The launch accompanied a milestone of more than 14,000 U.S. patients using NxStage systems for home hemodialysis.
3. TabloCart with Prefiltration – United States, 2024
   Outset Medical received FDA 510(k) clearance for TabloCart with Prefiltration, an optional accessory for its Tablo Hemodialysis System. The company resumed distribution of the product in the U.S. in May 2024, supporting greater flexibility for dialysis delivery from intensive-care settings to bedside treatment.
4. AWAK Wearable Artificial Kidney PD – Singapore, 2023
   AWAK Technologies and Singapore General Hospital launched a pre-pivotal clinical trial of an improved Automated Wearable Artificial Kidney Peritoneal Dialysis (AWAK PD) device. The wearable and ultra-portable system is designed to enable peritoneal dialysis outside conventional treatment environments and had received FDA Breakthrough Device Designation.
5. RENALYX-RxT 21 Smart Hemodialysis Machine – India, 2025
   Renalyx Health Systems introduced RENALYX-RxT 21, described as an indigenous AI- and cloud-enabled smart hemodialysis machine. The product represents the increasing integration of connected technologies, artificial intelligence, and digital monitoring into dialysis treatment in India.
6. Nikkiso DBB-06 PRO Hemodialysis Delivery System – United States, 2025
   Nikkiso’s DBB-06 PRO Hemodialysis Delivery System received U.S. FDA 510(k) clearance in May 2025. The development adds to the company’s dialysis equipment portfolio and reflects continued introduction of advanced hemodialysis delivery systems in the U.S. market.
7. Diality Moda-flx Hemodialysis System and Cartridge – United States, 2024
   The Moda-flx Hemodialysis System and Cartridge from Diality received FDA 510(k) clearance in August 2024. The system represents continued innovation in hemodialysis equipment and cartridge-based treatment technologies.
8. DEKA HemoCare Hemodialysis System – United States, 2024
   DEKA Research and Development’s HemoCare Hemodialysis System received FDA 510(k) clearance in July 2024. Its regulatory clearance represents another recent development in the U.S. hemodialysis equipment landscape.
9. Fresenius 5008X Hemodialysis System – United States, 2024
   Fresenius Medical Care received FDA 510(k) clearance for its 5008X Hemodialysis System in February 2024. The clearance enabled clinical evaluations and user studies for HVHDF in the United States and established a pathway toward broader commercialization of the therapy.
10. NxStage System One with Cartridge Express – United States, 2024
    The NxStage System One with Cartridge Express received U.S. FDA 510(k) clearance in March 2024. The development adds to the NxStage home and flexible dialysis technology portfolio and supports continued expansion of alternative approaches to conventional in-center dialysis.

United States Expanding Home Dialysis and Advanced Renal Care

United States dialysis market is supported by a large end-stage kidney disease population, established reimbursement systems, and extensive dialysis infrastructure. Hemodialysis remains the principal treatment modality, particularly in outpatient dialysis facilities, while home-based peritoneal dialysis (PD) and home hemodialysis (HHD) are gaining importance. According to the 2024 US Renal Data System (USRDS) Annual Data Report, the share of adults initiating dialysis with a home modality increased from 8.5% in 2012 to 14.5% in 2022, while home dialysis among prevalent dialysis patients also reached 14.5% in 2022. PD accounted for most home-dialysis growth, with 12.1% of prevalent patients receiving PD compared with 2.4% receiving home HD. The market is also benefiting from connected dialysis systems, remote monitoring, and patient-centered treatment models. However, disparities in home-dialysis adoption remain, with infrastructure and trained home-dialysis personnel influencing access. Continued innovation and efforts to expand home treatment are expected to support the U.S. dialysis market.

Germany Mature Healthcare Infrastructure Supporting Dialysis Demand

Germany dialysis market is characterized by advanced healthcare infrastructure, broad access to specialist medical services, and an ageing population requiring long-term renal care. Hemodialysis continues to represent an important treatment modality, while peritoneal dialysis provides an established home-based alternative for suitable patients. Germany’s mature healthcare system supports the operation of specialized nephrology practices, dialysis facilities, hospitals, and outpatient renal-care services. The country’s ageing demographic profile and increasing prevalence of diabetes, hypertension, and other chronic conditions create continuing demand for kidney replacement therapy. Healthcare providers are also increasingly interested in treatment approaches that improve patient convenience and reduce dependence on frequent facility visits, supporting interest in home dialysis and digital monitoring technologies. Germany’s established reimbursement and specialist-care structures provide an important foundation for dialysis service delivery, although staffing requirements and healthcare expenditure remain operational considerations. The market is therefore evolving toward more patient-centered and technology-enabled renal care, with demand supported by the need for continuous treatment among patients with advanced kidney failure.

India Government Programs and Rapid Expansion of Dialysis Access

India dialysis market is expanding as CKD, diabetes, and hypertension increase the need for renal replacement therapy, while government programs are improving access to treatment. The Pradhan Mantri National Dialysis Programme (PMNDP) has significantly expanded public dialysis infrastructure through government facilities and public-private partnerships. As of 31 July 2026, the PMNDP portal reported 1,874 dialysis centers across 36 States and Union Territories, 13,707 hemodialysis machines, 32.80 lakh patients who had availed dialysis services, and 446.87 lakh hemodialysis sessions. The program is designed to provide affordable or free dialysis services to eligible patients and supports both hemodialysis and peritoneal dialysis. Earlier government data showed that PMNDP benefited more than 4.53 lakh dialysis patients and delivered over 62.35 lakh hemodialysis sessions during FY2023–24. Expansion into district-level facilities, digital patient identification through ABHA, and the One Nation-One Dialysis approach are strengthening treatment accessibility. Growing private-sector investment and technological improvements are further supporting market development.

Saudi Arabia Healthcare Investment and Growing Renal-Care Infrastructure

Saudi Arabia dialysis market is supported by increasing demand for kidney replacement therapy, healthcare-sector investment, and the development of specialized renal-care infrastructure. Diabetes, hypertension, obesity, and population ageing contribute to the country’s long-term need for dialysis services. According to Saudi Arabia’s Ministry of Health 2023 Statistical Yearbook, the Ministry operated 223 dialysis centers or units nationwide in 2023. Riyadh accounted for 40, followed by Aseer with 21, Qassim with 19, and Eastern and Medina with 16 each. These facilities support the country’s established hemodialysis network, while peritoneal dialysis and home-care approaches provide additional treatment options for appropriate patients. Government investment is also strengthening dialysis capacity at the regional level. For example, a kidney center inaugurated at Al-Rain General Hospital was designed to provide 1,680 dialysis sessions annually. Saudi Arabia’s healthcare transformation agenda is encouraging digital technologies, specialized services, and patient-centered care. Continued investment in renal facilities, dialysis equipment, workforce capabilities, and chronic-disease management is expected to support market development.

Dialysis Market Segments

Type

• Peritoneal Dialysis
• Hemodialysis

Product & Services

• Services
• Equipment
• Consumables
• Drugs

End User

• Home Dialysis
• In Center Dialysis

Countries

North America

• United States
• Canada

Europe

• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• Netherlands
• Turkey

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Thailand
• Malaysia
• Indonesia
• New Zealand

Latin America

• Brazil
• Mexico
• Argentina

Middle East & Africa

• South Africa
• Saudi Arabia
• United Arab Emirates

All companies have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Key Players Analysis

• Asahi Kasei Corporation
• B. Braun Melsungen AG
• Baxter International Inc.
• Becton Dickinson and Company
• DaVita Inc.
• Fresenius Medical Care AG & Co. KGaA
• JMS Co. Ltd.
• Medtronic Plc.

Report Details: